Study Title

Phase 1/2, Open-Label Study of the Safety, Dosimetry and Efficacy of a 3-Dose Regimen of Escalating Doses of 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer

Study Details

Description:

Oncocytic (Hurthle cell) thyroid cancer (HTC) is a rare disease with few treatment options. Researchers are developing a radioactive drug that targets a protein that appears in high numbers on HTC cancer cells. Objective: To test a radioactive drug (177LuDOTA-EB-TATE) in people with HTC.

Sponsor:

National Institute of Diabetes and Digestive and Kidney Diseases

Contacts:

Joanna Klubo-Gwiezdzinska, M.D.

joanna.klubo-gwiezdzinska@nih.gov

(301) 496-5052

Padmasree Veeraraghavan, R.N.

padmasree.veeraraghavan@nih.gov

(301) 451-7710

Drug Details

Lu 177-DOTA-EB-TATE
Isotope(s):
    LUTETIUM-177
    Radioisotope: Lu-177
    Theranostic Role: Therapeutic Agent & SPECT Imaging
    T1/2 (Half-Life): 6.7 Days
    Decay Mode: BETA, GAMMA
    Energy: Eβeta max 497 keV, Gamma 113-208 keV
    Range: In Tissue: 0.25-2mm
    Decay Daughters: Hf177
    Status: FDA Approvals: PLUVICTO® (2022), LUTATHERA® (2017)
  • LUTETIUM-177
Target(s):
  • SSTR+
Ligand: Small Molecules
Chelator: DOTA
XCancer

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468